Abstract
The main obstacle to biopharmaceutical delivery in therapeutic concentration into the brain for treating neurological disorders is the presence of the Blood-Brain Barrier (BBB). The physiological process of Receptor-Mediated Transcytosis (RMT) to transport cargo through the brain endothelial cells toward brain parenchyma has prompted researchers to search for non-natural ligands that can be used to transport drugs across the BBB. Conjugation of drugs to RMT ligands would be an effective strategy for its delivery to the central nervous system. An attractive approach to identify novel transcytosing ligands is the screening by phage display combinatorial libraries. The main technology strength lies in the large variety of exogenous peptides or proteins displayed on the phage's surface. Here, we provide a mini-review of phage display technology using in vitro and in vivo BBB models for the development of peptide-mediated drug delivery systems.
Keywords: Phage display technology, blood-brain barrier, drug delivery, shuttle peptides, receptor-mediated transcytosis, molecular trojan horse.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Volume: 22 Issue: 11
Author(s): Viana M. Suárez, Nelson S. Vispo and Oliberto S. Ramos*
Affiliation:
- Department of Pharmacology, School of Biological Sciences, Universidad de Concepcion, Concepcion,Chile
Keywords: Phage display technology, blood-brain barrier, drug delivery, shuttle peptides, receptor-mediated transcytosis, molecular trojan horse.
Abstract: The main obstacle to biopharmaceutical delivery in therapeutic concentration into the brain for treating neurological disorders is the presence of the Blood-Brain Barrier (BBB). The physiological process of Receptor-Mediated Transcytosis (RMT) to transport cargo through the brain endothelial cells toward brain parenchyma has prompted researchers to search for non-natural ligands that can be used to transport drugs across the BBB. Conjugation of drugs to RMT ligands would be an effective strategy for its delivery to the central nervous system. An attractive approach to identify novel transcytosing ligands is the screening by phage display combinatorial libraries. The main technology strength lies in the large variety of exogenous peptides or proteins displayed on the phage's surface. Here, we provide a mini-review of phage display technology using in vitro and in vivo BBB models for the development of peptide-mediated drug delivery systems.
Export Options
About this article
Cite this article as:
Suárez M. Viana, Vispo S. Nelson and Ramos S. Oliberto *, Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier, Current Pharmaceutical Biotechnology 2021; 22 (11) . https://dx.doi.org/10.2174/1389201022666210104115224
DOI https://dx.doi.org/10.2174/1389201022666210104115224 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Current Medicinal Chemistry Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Role of Reactive Oxygen Species in Estrogen Dependant Breast Cancer Complication
Anti-Cancer Agents in Medicinal Chemistry A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Exploring Potential of Alkaloidal Phytochemicals Targeting Neuroinflammatory Signaling of Alzheimer's Disease
Current Pharmaceutical Design New Perspectives on Machine Learning in Drug Discovery
Current Medicinal Chemistry Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?
Current Alzheimer Research Neuroprotective Properties of Nicotine
Current Medicinal Chemistry Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders
Current Molecular Medicine Transplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders
Current Stem Cell Research & Therapy Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Current Protein & Peptide Science Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
CNS & Neurological Disorders - Drug Targets Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review
Current Alzheimer Research